Dr. O’Reilly holds the Winthrop Rockefeller Endowed Chair in Medical Oncology at MSK and leads the Hepatopancreaticobiliary and Neuroendocrine Cancers Section within the Gastrointestinal Oncology Service. Her academic appointments include Professor of Medicine at Weill Cornell and Co-Director for Medical Initiatives at the Rubenstein Center for Pancreatic Cancer Research. These roles place her at the nexus of bench discovery and bedside translation for malignancies that historically carry limited therapeutic latitude. Her portfolio includes federally supported projects such as an NCI-funded Specialized Program in Research Excellence that accelerates laboratory findings into early-phase trials for pancreatic ductal adenocarcinoma. Colleagues at international societies describe her as a galvanizing force who integrates molecular pharmacology, immuno-oncology, and patient-centred trial design to close longstanding outcome gaps.
Her investigative lens prioritises mechanisms of resistance and biomarker-guided treatment selection. Recent work evaluates KRAS-directed synthetic-lethality strategies, DNA-damage repair modulation, and stromal-targeted combinations that recalibrate an immunologically inert tumour micro-environment. These efforts underpin practice-changing studies such as the CABINET neuroendocrine-tumour trial, the zenocutuzumab programme for NRG1-fusion cancers, and the NALIRIFOX regimen that expanded first-line options for metastatic disease. She also co-authored state-of-the-art overviews in Nature Reviews Clinical Oncology and other journals that contextualise emerging data for clinicians worldwide. Such scholarship, coupled with an extensive mentoring footprint, sustains a pipeline of physician-scientists who propagate evidence-based protocols across academic and community settings.
Clinical interactions reflect the same analytic rigour. Multidisciplinary visits incorporate surgical, radiation, nutrition, and palliative specialists so that therapeutic intent aligns with each person’s values and physiologic reserve. Conversations distil complex genomics into clear next steps, enabling informed consent without overstated expectations. Patients emphasise her transparent style, while referring physicians note streamlined feedback loops that ease transitions between investigational and standard pathways. These attributes, together with sustained trial accrual, earned national recognition when she was inducted into the Giants of Cancer Care programme, underscoring her dual impact on discovery and day-to-day patient welfare.
Locations:
Cancer Treated:
Insurance
Insurance changes all the time, so please call and confirm if your insurance is accepted.
- AetnaAetna Medicare Advantage (MTA and NYC retirees only)Anthem BCBS and other BCBS licensee plansAnthem BCBS Health PlusHorizon Medicare AdvantageHealthfirst Medicare AdvantageFidelis Medicare AdvantageBlue Cross Blue Shield Federal Employee ProgramBlue Cross Blue Shield states outside of NY/NJCarrum HealthCignaConnectiCareStraight NJ MedicaidStraight NY MedicaidEmblemEmblem EssentialEmblem Medicare Advantage (Medicare Choice PPO Network and VIP Prime Network Only)Empire EssentialEmpire Plan / NYSHIP (Blue Cross/UnitedHealthcare split plan)FidelisFidelis Managed Medicaid & HARPFirst HealthHusky CT MedicaidHealthfirstHealthfirst Managed MedicaidHealthSmartHorizon Blue Cross Blue Shield New Jersey (HMO)Horizon Blue Cross Blue Shield New Jersey (PPO)Horizon Blue Cross Blue Shield New Jersey Omnia Tier I (EPO)Horizon Blue Cross Blue Shield New Jersey Omnia Tier II (EPO)NYC Medicare Advantage Plus for City EmployeesMagnaCareMedicare Part A&B (traditional Medicare)MetroPlusMultiplan/Beech Street/PHCSMVPNon-Participating Plans with Out of Network BenefitsOscarOxfordWorld Trade Center Health Program (WTC)QualCareTricareUMRUnited Healthcare